MOR106 + topical corticosteroids

MOR106 + topical corticosteroids is a combination investigational therapy evaluated in clinical trials for moderate to severe atopic dermatitis. MOR106 is a human monoclonal antibody targeting interleukin 17C (IL-17C), a cytokine implicated in epithelial inflammation and skin diseases. Topical corticosteroids are anti-inflammatory steroids used as standard therapy for atopic dermatitis. The combination was studied to assess whether blocking IL-17C by MOR106, in conjunction with topical steroid therapy, could improve symptoms and outcomes in moderate to severe atopic dermatitis. MOR106 did not demonstrate efficacy in these studies, though the combination was generally well-tolerated. The development program for this indication has been terminated due to lack of efficacy[1][3][5][6][7].

Brand names

MOR106 (no distinct brand names found for the combination)

Other names

MOR106 + topical corticosteroidsMOR106 plus topical corticosteroidsMOR-106 plus topical corticosteroidsMOR 106 plus topical corticosteroids